健康志愿者中抗体类替格瑞洛逆转剂的研究
这是一项随机、双盲、安慰剂对照的1期试验,评估单克隆抗体片段PB2452作为替格瑞洛逆转剂的效果。64名健康志愿者随机分配,48名接受PB2452,16名接受安慰剂。经过48小时替格瑞洛预处理后,血小板聚集被抑制约80%。给予PB2452(初始静脉推注后延长输注8、12或16小时)后,多种检测方法均显示血小板功能较安慰剂显著增加,逆转在开始给药后5分钟内发生,并持续超过20小时(Bonferroni校正后P<0.001)。停药后未发现血小板活性反弹,药物相关不良事件主要限于输注部位问题。
要点
- 在健康志愿者中,替格瑞洛预处理48小时后血小板聚集被抑制约80%。
- PB2452采用初始静脉推注后延长输注(8、12或16小时)的方案,可显著增加血小板功能,优于安慰剂。
- 替格瑞洛逆转在开始PB2452后5分钟内发生,并持续超过20小时(Bonferroni校正后所有时间点所有检测P<0.001)。
- 停药后未观察到血小板活性反弹。
- 药物相关不良事件主要限于输注部位问题。
适用人群与场景
- 健康志愿者,年龄等具体纳入排除标准原文未提及。
处置流程与药物剂量
- PB2452给药方案为初始静脉推注后延长输注8、12或16小时,具体剂量原文未提及。
研究设计与关键结果
- 研究类型为随机、双盲、安慰剂对照的1期试验,共纳入64名健康志愿者,48名分配至PB2452组,16名分配至安慰剂组。
- 替格瑞洛预处理48小时后,血小板聚集被抑制约80%。
- PB2452组血小板功能增加显著大于安慰剂组,采用光透射聚集法、床旁P2Y12血小板反应性检测和血管扩张剂刺激磷蛋白检测等多种方法评估。
- 逆转在开始PB2452后5分钟内发生,持续超过20小时,Bonferroni校正后所有时间点所有检测P<0.001。
- 停药后未发现血小板活性反弹。
- 药物相关不良事件主要限于输注部位问题。
证据类型、等级与局限
- 证据类型为随机、双盲、安慰剂对照的1期试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在健康志愿者中,PB2452可立即且持续逆转替格瑞洛的抗血小板效应,可能对接受替格瑞洛治疗的患者发生大出血或需紧急侵入操作时有用,但本研究为1期健康志愿者试验,临床获益需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ticagrelor is an oral P2Y12 inhibitor that is used with aspirin to reduce the risk of ischemic events among patients with acute coronary syndromes or previous myocardial infarction. Spontaneous major bleeding and bleeding associated with urgent invasive procedures are concerns with ticagrelor, as with other antiplatelet drugs. The antiplatelet effects of ticagrelor cannot be reversed with platelet transfusion. A rapid-acting reversal agent would be useful.
METHODS: In this randomized, double-blind, placebo-controlled, phase 1 trial, we evaluated intravenous PB2452, a monoclonal antibody fragment that binds ticagrelor with high affinity, as a ticagrelor reversal agent. We assessed platelet function in healthy volunteers before and after 48 hours of ticagrelor pretreatment and again after the administration of PB2452 or placebo. Platelet function was assessed with the use of light transmission aggregometry, a point-of-care P2Y12 platelet-reactivity test, and a vasodilator-stimulated phosphoprotein assay.
RESULTS: Of the 64 volunteers who underwent randomization, 48 were assigned to receive PB2452 and 16 to receive placebo. After 48 hours of ticagrelor pretreatment, platelet aggregation was suppressed by approximately 80%. PB2452 administered as an initial intravenous bolus followed by a prolonged infusion (8, 12, or 16 hours) was associated with a significantly greater increase in platelet function than placebo, as measured by multiple assays. Ticagrelor reversal occurred within 5 minutes after the initiation of PB2452 and was sustained for more than 20 hours (P<0.001 after Bonferroni adjustment across all time points for all assays). There was no evidence of a rebound in platelet activity after drug cessation. Adverse events related to the trial drug were limited mainly to issues involving the infusion site.
CONCLUSIONS: In healthy volunteers, the administration of PB2452, a specific reversal agent for ticagrelor, provided immediate and sustained reversal of the antiplatelet effects of ticagrelor, as measured by multiple assays. (Funded by PhaseBio Pharmaceuticals; ClinicalTrials.gov number, NCT03492385.).
参考来源
- Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. N Engl J Med. 2019. PMID: 30883047. doi:10.1056/NEJMoa1901778
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。